Effectiveness of SMS (Short Message Service) Text Messaging in Increasing Adherence to Gardasil (CHAT)
A Randomized, Controlled Trial to Compare the Effectiveness of SMS Text Message Reminders Compared to Usual Care to Increase Adherence to the Gardasil Vaccine Dosing Schedule (GCC 1063GCC).
Sponsor: Merck Sharp & Dohme LLC
Terminated
Unable to recruit sufficient sample for study completion.
Other terminated trials from Merck Sharp & Dohme LLC
- Melanoma · Phase PHASE2 · Feb 2026
- Advanced Solid Tumor · Phase PHASE2 · Jan 2026
- Lung Cancer Metastatic · Phase PHASE1/PHASE2 · Dec 2025
- Advanced and Metastatic Urothelial Cancer · Phase PHASE2 · Sep 2025
- Malignant Solid Tumor · Phase PHASE1 · Aug 2025
More terminations from Merck Sharp & Dohme LLC
Listed as NCT01276184, this NA trial focuses on HPV Vaccines and remains terminated or withdrawn. Sponsored by Merck Sharp & Dohme LLC, it has been updated 10 times since 2011, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jan 2023 — Jul 2024 [monthly]
Terminated NA
-
Dec 2022 — Jan 2023 [monthly]
Terminated NA
-
Jun 2022 — Dec 2022 [monthly]
Terminated NA
▶ Show 5 earlier versions
-
Sep 2021 — Jun 2022 [monthly]
Terminated NA
Status: Unknown Status → Terminated
-
Jan 2021 — Sep 2021 [monthly]
Unknown Status NA
-
Sep 2019 — Jan 2021 [monthly]
Unknown Status NA
-
Jun 2018 — Sep 2019 [monthly]
Unknown Status NA
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status NA
First recorded
Jan 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
- University of Maryland, Baltimore
For direct contact, visit the study record on ClinicalTrials.gov .